Voltage-gated sodium (Na v ) channels are embedded in a multicomponent membrane signaling complex that plays a crucial role in cellular excitability. Although the mechanism remains unclear, β-subunits modify Na v channel function and cause debilitating disorders when mutated. While investigating whether β-subunits also influence ligand interactions, we found that β4 dramatically alters toxin binding to Na v 1.2. To explore these observations further, we solved the crystal structure of the extracellular β4 domain and identified 58 Cys as an exposed residue that, when mutated, eliminates the influence of β4 on toxin pharmacology. Moreover, our results suggest the presence of a docking site that is maintained by a cysteine bridge buried within the hydrophobic core of β4. Disrupting this bridge by introducing a β1 mutation implicated in epilepsy repositions the 58 Cys-containing loop and disrupts β4 modulation of Na v 1.2. Overall, the principles emerging from this work (i) help explain tissuedependent variations in Na v channel pharmacology; (ii) enable the mechanistic interpretation of β-subunit-related disorders; and (iii) provide insights in designing molecules capable of correcting aberrant β-subunit behavior.
V
oltage-gated sodium (Na v ) channels play a key role in cellular communication by manipulating the transmembrane voltage gradient to encode and propagate vital information rapidly over long distances (1) . Consequently, mutations that modify Na v channel activity underlie debilitating neurological diseases, muscular disorders, and pain syndromes (2, 3) . Typically, Na v channels are part of a membrane-embedded signaling complex that involves various integral membrane proteins (4) . The significance of this environment for proper channel function is highlighted by divergent Na v channel responses to changes in membrane voltage when expressed in native tissues or in heterologous systems. β-Subunits are prominent members of the Na v channel signaling complex but do not contribute to the ion-conducting pore (5) . Instead, they are multifunctional single-transmembrane segment glycoproteins that (i) modulate the gating properties of voltagegated ion channels; (ii) regulate Na v channel trafficking and expression levels; and (iii) promote cell adhesion and migration (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Of the four known β-subunits and their splice variants (15) (16) (17) (18) (19) (20) , β4 is unique in that it enables resurgent current, a feature that renders certain Na v channel isoforms capable of high-frequency firing in excitable tissues (21) . Moreover, aberrant behavior of the ubiquitously expressed β4 subunit has been implicated in long-QT syndrome (LQTS) (22) , LQTS-associated Sudden Infant Death Syndrome (23) , atrial fibrillation (24), Huntington's disease (25) , and prostate cancer (26) , possibly through dysregulation of the Na v channel signaling complex. β4 also is targeted by β-and γ-secretase enzymes from the amyloidogenic pathway, a recent observation that suggests a potential contribution of this particular subunit to the development of Alzheimer's disease (27) .
Despite accumulating evidence supporting an important contribution to neuronal excitability and various health disorders (28) , fundamental questions about the molecular mechanisms underlying β4 interaction with Na v channels remain unanswered.
Moreover, the notion that the β4 subunit shapes the overall pharmacological sensitivities of the Na v channel signaling complex remains unexplored. However, altered ligand interactions may be exploited to detect the presence of β4 in normal or pathological conditions (29) . Here, we investigated whether β-subunits influence Na v channel sensitivity to molecules isolated from animal venom and discovered that β4 can drastically alter the response of the neuronal Na v 1.2 isoform to spider and scorpion toxins that target paddle motifs within Na v channel voltage sensors. To elucidate the machinery underlying this observation, we solved the crystal structure of the extracellular β4 domain and found a 58 Cys-containing binding interface that is involved in Na v channel modulation of toxin pharmacology by β4. Remarkably, dismantling the strictly conserved internal cysteine bridge in β4 by introducing a β1 mutation implicated in epilepsy (30) does not preclude protein folding and trafficking to the membrane. However, conformational changes induced by the mutation perturb the 58 Cys-containing loop and disrupt β4 interaction with Na v 1.2, in turn altering the functional and pharmacological properties of the larger Na v channel signaling complex.
Results β-Subunits Shape Na v Channel Pharmacology. Although the influence of β-subunits on ion channel gating is well documented (5), little is known about their ability to manipulate the pharmacological sensitivities of Na v channel signaling complexes (29, 31, 32) . To investigate the extent to which these versatile glycoproteins modify ligand interactions, we applied seven toxins from spider, scorpion, sea anemone, and wasp venom (ProTx-I, ProTx-II, TsVII, AaHII,
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LqqIV, ATX-II, and β-PMTX) as well as two drugs (lidocaine and ambroxol) to Xenopus oocytes expressing the neuronal Na v 1.2 isoform and determined potential changes in ligand susceptibility induced by the presence of each of the four β-subunits. We uncovered multiple conditions in which Na v 1.2's sensitivity to a particular toxin was modified by β-subunits, whereas sensitivity to neither drug was significantly affected (Fig. 1, Fig. S1 , and Table  S1 ). For example, the sea anemone toxin ATX-II interacts exclusively with the Na v 1.2 domain IV voltage sensor to inhibit fast inactivation, resulting in a large increase in inward sodium ion flow (33) . When β2 is present, 100 nM ATX-II still prevents Na v 1.2 from inactivating rapidly; however, the peak sodium current increases only marginally (Fig. S1) . A similar effect is seen when 100 nM of the domain IV-targeting scorpion toxin LqqIV is applied to Na v 1.2 coexpressed with β1 [binding site identification is given in Fig. S2  (34) ]. In this instance, however, LqqIV also shifts the steady-state inactivation curve to more positive potentials (V 1/2 from −57 mV to −48 mV; P ≤ 0.001), thereby increasing channel availability to open in response to membrane depolarizations (Fig. S1 ). In contrast, the related scorpion toxin AaHII (34) decreases Na v 1.2 availability when coexpressed with β2 (V 1/2 from −42 mV to −61 mV; P ≤ 0.001) or β4 (V 1/2 from −45 mV to −63 mV; P ≤ 0.001).
Interestingly, the most striking effects on toxin susceptibility are observed when Na v 1.2 is expressed together with the β4 subunit. First, the tarantula toxin ProTx-II has been shown to interact with the voltage sensors in domains I, II, and IV of Na v 1.2 and to inhibit channel opening (34, 35) . However, in the presence of β4, Na v 1.2 is dramatically less inhibited, suggesting that β4 may prevent ProTx-II from interacting with one or more of its receptor sites (Fig. 1B) . Second, the structurally unrelated scorpion toxin TsVII promotes Na v channel opening by preferentially interacting with the voltage sensor in domain II and stabilizing it in an activated state (34, 36) . Without β-subunits present, 500 nM TsVII causes Na v 1.2 to open at more negative voltages, although the maximal conductance of the channel is not affected. In contrast, TsVII greatly decreases Na v 1.2 maximal conductance with a smaller shift in activation voltage when β4 is present (Fig.  1C) , raising the possibility that this β-subunit exerts an influence on the domain II voltage sensor. Next, we crystallized the extracellular β4 domain to explore the mechanisms underlying the influence of this particular β-subunit on Na v 1.2 pharmacology.
The β4 Subunit Structure Reveals an Exposed Cysteine. Despite their impact on the functional and pharmacological properties of Na v channels, tertiary structural information about β-subunits has been lacking. To address this inadequacy, we solved the crystal structure of the extracellular β4 domain (residues 32-157) at 1.7-Å resolution (Fig. 2, Fig. S3 , and Table 1 ) and found that this subunit has a compact fold, similar to that of immunoglobulins, that consists of 10 β-strands and two 3 10 helices (37, 38) . A low sequence complexity suggests that the upstream region of this domain (residues 1-31) is likely to be disordered in the absence of a binding partner, because constructs containing this particular segment result in protein aggregation. Moreover, a large portion of this region also may serve as a membrane-targeting signal sequence that is proteolytically cleaved during cellular processing (19) . Overall, the structure is held together by a buried disulfide bridge connecting the β 2 -β 3 loop with the β 8 -strand which is flanked by 68 Trp, a residue conserved among all β-subunit isoforms. On the other side, it packs against 114 Ile and 133 Val, both of which correspond to the similar Ile, Val, or Leu residues in other β-subunits (Fig. 2C) . Because of the strictly conserved nature of the protein core (Fig. 2D) , it is likely that the buried disulfide bond has a major effect on the stability of the protein. Another stabilizing element in the β4 structure is an ionpair network involving two hydrogen bonds between 98 Asp and 100 Arg, which forms two additional bonds with 125 Asp, as well as a hydrogen bond between 77 Lys and 125 Asp that is mediated by a water molecule (Fig. 2E ). Such networks of ionic pairs are more stabilizing than individual salt bridges because of lower desolvation penalties (39) . Next, we examined the surface of β4 for unique structural features that may contribute to an interaction with Na v 1.2.
The β4 extracellular domain consists of solvent-accessible surface area of ∼6,600 Å 2 with one side exposing multiple hydrophobic side chains as well as residue 58, a Cys in WT protein but replaced by Ala to facilitate crystallization (Fig. 3A) . 58 Cys is located in a loop between the β 2 -and β 3 -strands and is lined by two hydrophobic pockets, thereby placing it in an ideal position to form a disulfide bond with another free Cys ( Fig. 2A) . Nonetheless, conformational changes resulting from the C58A mutation are unlikely, because the residue is located at the protein surface, and the mutant has a thermal stability similar to that of WT β4 (Fig.  3B) . Strikingly, the position of 58 Cys in β4 corresponds to that of the Cys ( 26 Cys) thought to be involved in linking β2 to Na v 1.1 (40) . Here, removing the covalent bond with Na v 1.1 by mutating 26 Cys to Ala results in an altered subcellular localization pattern of β2. Given the prominent position of 58 Cys in the β4 crystal structure and the functional importance of the corresponding residue in β2, we asked whether 58 Cys plays a role in determining the influence of β4 on Na v 1.2 toxin pharmacology.
Mutating 58
Cys in β4 Restores Na v 1.2 Sensitivity to ProTx-II. To examine whether the ability of β4 to alter Na v 1.2 toxin susceptibility Table S1 . n = 3-5; error bars represent S.E.M.
depends on a disulfide bond involving 58 Cys, we initially incubated Na v 1.2/β4-expressing oocytes with a reducing agent (DTT) for 60 min. Subsequently, we transferred the oocyte to a physiological recording solution and tested whether Na v 1.2 regains sensitivity to ProTx-II (Fig. S4 ). Even though all exposed cysteines may have been reduced, channel-gating behavior is not affected significantly; however, we observe that the toxin now inhibits Na v 1.2 as if no β4 is present, suggesting that the disulfide bond between 58 Cys and Na v 1.2 is crucial in modifying channel susceptibility to ProTx-II in the presence of β4.
Next, we replaced 58 Cys in β4 with Ala and exploited the presence of an intracellular Myc-tag to determine whether cellular trafficking of this mutant is altered. By doing so, we discovered that the WT β4 protein and the C58A mutant are produced in large quantities (Fig. 4A) . Moreover, biotinylation experiments reveal the presence of both variants within the lipid membrane, most likely in a glycosylated form (41) . When β4 glycosylation is removed using peptide-N-glycosidase F (PNGase F), an amidase that releases N-linked oligosaccharides, the molecular weight of the protein on the membrane surface corresponds to the predicted mass of β4 (28 kDa) ( Fig. S5) (19) . Having established the membrane insertion of β4 and the C58A mutant (without or in the presence of Na v 1.2; Fig. S5) , we next applied 100 nM ProTx-II to cells expressing Na v 1.2/β4 C58A and observed a level of inhibition similar to that obtained when no β4 is present ( Fig. 4 B and C) . When comparing the affinities of ProTx-II for Na v 1.2 in more detail, we note an approximately fivefold decrease in the presence of β4 compared with control conditions without β4 (IC 50 from 32 ± 1 nM to 164 ± 33 nM with slopes of 1.9 ± 0.1 and 1.6 ± 0.3, respectively). Moreover, the affinity of ProTx-II for Na v 1.2 coexpressed with the C58A mutant (IC 50 = 33 ± 2 nM with a slope of 1.7 ± 0.1) is comparable to the IC 50 obtained on cells lacking β4 (Fig. 4D) . Taken together, our results identify 58 Cys as a reactive residue that, when mutated, eliminates the influence of β4 on Na v 1.2 toxin pharmacology by perturbing a unique disulfide bond with the Na v channel.
Mapping Clinically Relevant β-Subunit Mutations onto the β4 Structure.
Reflecting its medical importance, atypical β-subunit behavior has been implicated in various epilepsy syndromes and cardiac disorders (5). However, little is known about the relationship between the structural and functional consequences of mutations and a particular clinical phenotype. Our results presented here provide a unique opportunity to map abnormalities within the extracellular domain onto a high-resolution β4 crystal structure and to explore their mode of action ( Fig. 5 and Table S2 ). For example, R85H and E87Q in β1 have been associated with atrial fibrillation and Brugada syndrome, respectively (42, 43) . Both residues are located near or within the β 5 -β 6 loop and form a patch of solvent-accessible surface area (Fig. 5A) , suggesting that these amino acids are part of an important functional interface that may be targeted by therapeutics (28) . Similarly, the R125L variant has been identified in patients who have generalized epilepsy plus febrile seizures plus (GEFS+) (44) , whereas R125C may contribute to the occurrence of Dravet syndrome (45) . Because this residue lines a pocket near the conserved 58 Cys, the addition of a Cys may interfere with the formation of a proper disulfide bond with the Na v channel (Fig. 5A) .
Surface-exposed mutations may hint at a disruption of a functional interface, whereas buried substitutions are likely to affect overall protein folding. For instance, in patients who suffer from Dravet syndrome (46) a Pro residue replaces a concealed Ile at position 106 in β1, where it is likely to interfere with protein folding (Fig. 5A) . The V110I mutation in β3 has been linked to Brugada syndrome and also affects a residue buried within a hydrophobic core, resulting in reduced channel expression (47) . Interestingly, the first epileptogenic mutation attributed to Nav channel β-subunits is a Cys-to-Trp substitution that disrupts the disulfide bridge within the extracellular domain of β1 (30) . Although the protein traffics to the membrane, the precise mechanism relating this C121W variant to the resulting GEFS+ disease phenotype is still a matter of debate (48) (49) (50) . We chose to mutate the corresponding residue in β4 (C131W and C131A) to determine whether disrupting this strictly conserved internal disulfide bond repositions 58 Cys to such an extent that it cannot interact with the Na v channel.
Even though a lack of space for a Trp side chain at the 131 Cys position suggests that this mutant should be unable to fold properly and aggregate, both the C131W and the C131A construct can be purified to obtain nonaggregated protein, as indicated by sizeexclusion chromatography (Fig. S6) . Moreover, thermal stability measurements in the presence of reducing agent [14 mM 2-mercaptoethanol (2-ME)] only show ∼4-°C and ∼7-°C decreases in melting temperatures for C131W and C131A, respectively, compared with WT (Fig. 3B) . The presence or absence of 2-ME did not affect the melting curves for the two mutants, and we did not observe an interpretable melting curve for WT β4 without reducing agent, an observation that is consistent with the major stabilizing effect of a disulfide bond. Taken together, these results demonstrate that, although the disulfide bond adds to stability, it is not strictly required for folding.
To explore this surprising result further, we next solved the crystal structure of the C131W construct at a resolution of 1.7 Å and found that the mutation results in conformational changes at multiple positions (Fig. 5B) . Because the location of 144 His in the β 9 -β 10 loop would clash with the bulky Trp residue, this residue has swung away completely, and the β 9 -β 10 loop adopts a β-strand conformation that results in a merged β 9 -β 10 strand. In addition, 53 Cys no longer is constrained by the disulfide bond, resulting in a dramatic shift of the β 2 -β 3 loop (∼5.2 Å) within the main chain. This shift of the β 2 -β 3 loop in turn shifts the positions of the neighboring β 4 -β 5 loop (∼6 Å) and the β 6 -β 7 loop (∼6.8 Å), resulting in complete remodeling of the surface. Because the β 2 -β 3 loop contains the functionally important 58 Cys residue, the C131W mutation remodels the Na v channel-binding interface, potentially altering the functional and pharmacological properties of the Na v channel signaling complex. To substantiate this notion, we tested whether the C131W mutant indeed loses its ability to modify Na v 1.2 sensitivity to ProTx-II.
The C131W Mutation Alters the Influence of β4 on Na v 1.2 Toxin Pharmacology. To examine the effect of the C131W substitution on Na v 1.2 toxin susceptibility, we first determined whether cellular trafficking of this mutant is altered. Similar to WT β4, C131W is produced in large amounts (Fig. 6A) ; however, a nonquantitative Western analysis of total cell lysate uncovers potential alterations in glycosylation patterns that may complicate protein separation from the endoplasmatic reticulum. Nonetheless, biotinylation experiments reveal the presence of C131W within the oocyte membrane ( Fig. 6A and Fig. S5 ). Indeed, when glycosylation is removed using PNGase F, the molecular mass of the C131W mutant on the membrane surface closely matches the predicted mass of β4 (19) . These results are consistent with previously reported observations with the β1 C121W mutant in a mouse model for epilepsy (51) and in human embryonic kidney cells stably expressing Na v 1.1 (6). Subsequently, we applied 100 nM ProTx-II to cells expressing Na v 1.2/β4 C131W and observed a level of inhibition over a wide voltage range similar to that obtained when neither β4 nor the C58A mutant is present (Fig. 6 B and C) . Because the C131W mutant traffics to the membrane surface in oocytes, results from the ProTx-II experiment suggest that 58 Cys no longer may be able to interact with Na v 1.2. It is worth noting that our Western blot analysis ( Fig. 6A and Fig. S5 ) does not rule out the possibility that impaired C131W trafficking in oocytes may contribute, at least in part, to the restoration of Na v 1.2 toxin sensitivity. Together with our crystallographic data, these functional results show that, although the conserved cysteine bond is not strictly required to produce folded protein, it does dictate the overall conformation, including the position of the important 58 Cyscontaining bioactive surface. Discussion β-Subunits are vital members of the larger Na v channel signaling complex in which they modify channel function to fine-tune the electrical excitability of native tissues (5-7, 9, 52). The goal of the present study was to investigate the interaction of β-subunits with Na v channels on a molecular level and the role of these ancillary proteins in shaping the pharmacological sensitivities of the neuronal Na v 1.2 isoform. Our experiments with an extensive collection of animal toxins establish that β-subunits can alter Na v 1.2 pharmacology drastically and that the resulting effects vary among β-subunit-toxin pairs (Fig. 1, Fig. S1 , and Table S1 ). For example, β4 coexpression results in an approximately fivefold decrease in the affinity of ProTx-II for Na v 1.2, whereas the same subunit reduces sodium influx upon TsVII application, an effect that is not observed with the WT channel or in the presence of β1-3. It is worth considering potential principles underlying β-subunit modulation of Na v channel pharmacology. For example, a toxin may compete with a β-subunit for binding to a particular region within Na v 1.2. For instance, LqqIV interacts with the domain IV voltage sensor (Fig. S2) , and its effect is influenced by β1, suggesting a direct or allosteric interaction of this particular subunit with domain IV within Na v 1.2 (53) (54) (55) . Alternatively, ligands may bind directly to β-subunits (56), an intriguing concept that also has been observed with the voltagegated calcium channel inhibitor gabapentin, which acts through the transmembrane α2δ subunit (57) . Interestingly, β3 is unable to modulate Na v 1.2 susceptibility to any of the toxins we tested, but this particular subunit influences lidocaine binding to the neonatal Na v 1.3 and cardiac Na v 1.5 isoform (58, 59) . This result highlights the unique character of the interaction between a particular β-subunit and a given Na v channel isoform (60) .
Because the most striking effects on Na v 1.2 toxin susceptibility are observed with the β4 subunit, we crystallized its extracellular domain and identified 58 Cys as a surface-exposed residue that, when mutated, abolishes the impact of β4 on ProTx-II binding to Na v 1.2 (Figs. 2 and  3 ). Because this Cys is conserved in β2 and β4, it likely belongs to a universal docking site for multiple Na v 1 channel isoforms. The two other conserved cysteines ( 53 Cys and 131 Cys) are buried within a hydrophobic core where they form a disulfide bond. When 131 Cys is mutated to Trp or Ala (Fig. 3B) , we surprisingly find that the extracellular domain is still folded, thus demonstrating that the cysteine bridge is not strictly required to produce functional protein. However, the crystal structure of the C131W mutant, which mimics a well-established epileptogenic mutation found in β1, reveals conformational changes at multiple locations, including the loop that contains the conserved 58 Cys (Fig. 5B) . Subsequently, an important role of the buried cysteine bridge may be to maintain a specific local structure that allows an interaction with the Na v channel and that, when disrupted (Fig. 6) , creates a lossof-function phenotype that relates to disorders such as GEFS+ (30) .
Collectively, the functional and crystallographic results reported here shed light on the intricate interactions of β4 within the Na v channel signaling complex and establish a key role for β-subunits in shaping Na v 1.2 pharmacology. As such, an important concept emerging from our work is that β-subunits provide exciting opportunities for designing new therapeutic strategies to correct their abnormal behaviors.
Materials and Methods
Toxin Acquisition and Purification. ProTx-I and ProTx-II (61) were acquired from Peptides International, β-PMTX (62) was obtained from Alomone Laboratories, and ATX-II (63), lidocaine, and ambroxol were from SigmaAldrich. AaHII from Androctonus australis hector venom, TsVII from Tityus serrulatus venom, and LqqIV from Leiurus quinquestriatus were purified as described previously (64) (65) (66) . Toxins were kept at −20°C, and aliquots were dissolved in appropriate solutions containing 0.1% BSA. Table S2 ) mapped onto the β4 extracellular domain. The corresponding residue substitutions are shown in parentheses, and the positions of 53 Cys and 58 Cys are indicated by a yellow stick for reference purposes. Two mutations occur within inserted regions, and the main chains of amino acids next to these insertions are also colored black. (B) The crystal structure of the C131W mutant (white) superimposed onto the WT β4 crystal structure (blue). Shifts in the positions of several regions are indicated by double-headed arrows, and select side chains are shown for reference purposes. 58 Cys in the C131W structure appears to have a 2-ME molecule attached to it, further highlighting its reactivity. In both A and B, mutants discussed in this work are displayed in red.
Two-
, and of the C58A and C131W mutants were confirmed by automated DNA sequencing, and cRNA was synthesized using T7 polymerase (mMessage mMachine kit; Ambion) after linearizing the DNA with appropriate restriction enzymes. LqqIV binding site experiments on chimeric voltage-gated potassium channels were carried out as previously described (34) . Channels were expressed together with a β-subunit (1:5 molar ratio) in Xenopus oocytes that were incubated at 17°C in 96 mM NaCl, 2 mM KCl, 5 mM Hepes, 1 mM MgCl 2 , 1.8 mM CaCl 2 , and 50 g/mL gentamycin (pH 7.6) with NaOH for 1-2 d after cRNA injection, and then were studied using two-electrode voltage-clamp recording techniques (OC-725C; Warner Instruments) with a 150-μL recording chamber. Data were filtered at 4 kHz and digitized at 20 kHz using pClamp 10 software (Molecular Devices). Microelectrode resistances were 0.5-1 MΩ when filled with 3 M KCl. The external recording solution (ND100) contained 100 mM NaCl, 5 mM Hepes, 1 mM MgCl 2 , and 1.8 mM CaCl 2 (pH 7.6) with NaOH. All experiments were performed at room temperature (∼22°C). Leak and background conductances, identified by blocking the channel with tetrodotoxin (Alomone Laboratories), have been subtracted for all Na v channel currents. All chemicals used were obtained from Sigma-Aldrich unless otherwise indicated.
Analysis of Channel Activity and Toxin-Channel Interactions. Voltage-activation relationships were obtained by measuring steady-state currents and calculating conductance (G). In representative cases a Boltzmann function was fitted to the data according to: G=G max ¼ ð1 þ e -zFðV-V1=2 Þ=RT Þ -1 where G/ G max is the normalized conductance, z is the equivalent charge, V 1/2 is the half-activation voltage, F is Faraday's constant, R is the gas constant, and T is temperature in Kelvin. Occupancy of closed or resting channels by ProTx-II and other toxins was examined using negative holding voltages when open probability was very low, and the fraction of uninhibited channels (Fu) was estimated using depolarizations that are too weak to open toxin-bound channels, as described previously (34) . After the toxin was added to the recording chamber, the equilibration between the toxin and the channel was monitored using weak depolarizations elicited at 5-s intervals. Concentration dependence for ProTx-II inhibition of Na v channels is plotted as Fu measured at negative voltages versus toxin concentration. A Hill equation was fitted the data to obtain affinity values. Off-line data analysis was performed using Clampfit 10 (Molecular Devices) and Origin 8 (OriginLab).
Nonquantitative Biochemical Assessment of β4 Production in Xenopus Oocytes. Batches of 20 oocytes expressing Na v 1.2, Na v 1.2/β4, Na v 1.2/β4 C58A, and Na v 1.2/β4 C131W were washed with ND100 and incubated with 0.5 mg/mL Sulfo-NHS-LC-biotin (Pierce) for 30 min. Oocytes were thoroughly washed again (by pipetting up and down) in ND100 before lysis in 400 μL buffer H (1% Triton X-100, 100 mM NaCl, 20 mM Tris·HCl, pH 7.4) plus protease inhibitors (Clontech). All subsequent steps were performed at 4°C. Lysates were shaken gently for 15 min and then were centrifuged at 16,200 × g for 3 min. The pellet was discarded, and the supernatant was transferred to a fresh 1.5-mL Eppendorf tube; 40 μL of supernatant was stored at −80°C for later use as the whole-cell protein aliquot. Then 200 μL of hydrophilic streptavidin magnetic beads (New England Biolabs) was added, and the sample was shaken gently at 4°C overnight. Beads were washed six times with buffer H and were resuspended in 40 μL buffer H, after which biotinylated protein was dissociated from the beads by the addition of 40 uL 1× LDS loading buffer plus reducing agent [final concentration: 10% (vol/vol) 2-ME, 50 mM DTT] and boiling at 95°C for 5 min. Deglycosylated samples were prepared by incubating the surface protein aliquot with PNGase-F and 1% Nonidet P-40 at 37°C for I h. All samples were diluted appropriately in buffer H to give roughly equal protein concentrations, as measured by absorbance at 280 nM. Then 7.5 μL of the supernatant was run on a 10% (wt/ vol) Bis-Tris NuPAGE Novex Mini-Gel (Invitrogen) with 3-(N-morpholino) propanesulfonic acid running buffer and were analyzed by Western blot analysis. Nitrocellulose membranes were probed with 1:1,000 mouse antiMyc antibody (Cell Signaling Technologies) as the primary antibody and 1:10,000 goat anti-mouse HRP-conjugated antibody (Thermo-Fisher Scientific) as the secondary antibody. Membranes were incubated for 5 min with an enhanced chemiluminescent substrate (68) before imaging.
Production of the β4 Extracellular Domain. Human β4 (hβ4) (32-157) acquired from OriGene was cloned into pET28HMT (69) . Mutations were introduced using the QuikChange kit from Stratagene according to the manufacturer's instructions. Proteins were expressed at 18°C in Escherichia coli Rosetta (DE3) pLacI strains (Novagen), were induced at an OD 600 of ∼ 0.6 with 0.3 mM isopropyl β-D-1-thiogalactopyranoside, and were grown overnight before harvesting. Cells were lysed via sonication in buffer A (250 mM KCl and 10 mM Hepes, pH 7.4) supplemented with 25 μg/mL DNaseI and 25 μg/mL lysozyme. After centrifugation, the supernatant was applied to a PorosMC column (Tosoh Biosep), washed with buffer A plus 10 mM imidazole, and eluted with buffer B (250 mM KCl plus 500 mM imidazole, pH 7.4). The protein was dialyzed overnight against buffer A and cleaved simultaneously with recombinant TEV protease. Next, the samples were run on another PorosMC column in buffer A, and the flowthrough was collected and dialyzed against buffer C (50 mM KCl plus 20 mM Tris·Cl, pH 8.0), applied to a HiloadQ column (GE Healthcare), and eluted with a gradient from 0-30% buffer D (2 M KCl plus 20 mM Tris·Cl, pH 8.0). Finally, the samples were run on a Superdex200 gel-filtration column (GE Healthcare) in buffer A. The protein samples were exchanged with 25 mM KCl plus 10 mM Hepes (pH 7.4), concentrated to 10-20 mg/mL using Amicon concentrators (3 K molecular weight cut off; Millipore), and stored at −80°C.
Crystallization, Data Collection, and Structure Solution. Crystals were grown using the sitting-drop method at 4°C. β 4 (32-157) C58A was crystallized in 0.1 M Hepes (pH 7) and 15% (wt/vol) PEG 20000. The C131W mutant was crystallized in 0.2 M ammonium formate, 20% (wt/vol) PEG formate, and 20% (wt/vol) PEG 3350 at 4°C. Crystals were flash-frozen after transfer to the same solution supplemented with 30% (vol/vol) glycerol. Diffraction experiments were performed at the Advanced Photon Source (Chicago) beamline 23-ID-D-GM/CA, and datasets were processed using XDS (70) . A search model was created by using only β-strands from Protein Data Bank (PDB) ID code 1NEU and with all side chains truncated to Ala. Molecular replacement was performed using Phaser (71), yielding poor initial phases which were improved via autobuilding in ARP/wARP (72) . The model was completed by successive rounds of manual model building in COOT (73) and refinement using Refmac5.5 (74) . A simulated annealing composite omit map was calculated with CNS (75) to verify the absence of residual model bias. No residues were found to be in disallowed regions of the Ramachandran plot. All structure figures were prepared using Thermal Melting Experiments. The protein melting curves were measured by means of ThermoFluor experiments (69, 76) . Samples for melting curves contained 50 μL of 0.1 mg/mL protein and 1× SYPRO Orange solution (Invitrogen) using the manufacturer's instructions. The curves were measured in a DNA engine Opticon 2 real-time PCR machine (Bio-Rad), using the SYBR green filter option. The temperature was ramped from 25-95°C in 0.5-°C steps, with 15 s at each step. The melting temperatures were taken as the midpoint of each transition.
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Gilchrist et al. 10 .1073/pnas.1314557110 2/β4-expressing oocytes are shown before (black circles) and after (red circles) the application of 100 nM ProTx-II in control (no incubation; panels 1 and 3) and after 60 min incubation with 200 μM DTT and 100 μM EDTA (panels 2 and 4). As shown in this figure, Na v 1.2 opening is not significantly affected by the treatment; however, Cys reduction results in an increased affinity of ProTx-II for the Na v channel in the presence of β4. Channel-expressing oocytes were depolarized in 5-mV steps from a holding potential of −90 mV. n = 3-5; error bars represent S.E.M. (B) Representative sodium currents are elicited by a depolarization to −20 mV before (black) and after (red) the addition of 100 nM ProTx-II from a holding potential of −90 mV. The x-axis is 10 ms; the y-axis is ∼0.5 μA. Although several β2 and β4 mutations have been implicated in atrial fibrillation and LQTS in humans, the amino acid substitutions involved occur outside of the crystal structure reported in this work and are not represented in this table. GEFS+: generalized epilepsy plus febrile seizures plus. *Mutation found in a screen of colorectal cancer sample. The pathogenicity of the mutation has not been established, but the same position is also affected in a β1 mutation. † Accessible surface area is for the side chain of the WT residue only.
